

Amendments to the Specification:

Amend the title as follows:

Polypeptides ~~and their uses~~ Related to Amyloid Precursor Protein, Pharmaceutical Compositions Thereof, and Methods of Treatment Using the Same

Please replace the paragraph at page 20, lines 23-35 with the following amended paragraph:

Figures 5 and 6 show the effect of inducing memory loss by injection of a 16-mer end-protected phosphodiester oligodeoxynucleotide designed to correspond to the transcription start sites 146 and AUG₁₇₈₆ of the APP mRNA, immediately upstream of a ribozyme binding site. The oligodeoxynucleotide, 5' -CCC GAG GAC TGA GCC A-3' (SEQ ID No: 9 12) was further modified on the 2nd and 13th nucleotides to prevent internal looping and is available from King's College Molecular Medicine Unit, London, UK. The oligodeoxynucleotide was used in scrambled (SC) and antisense (AS) forms and administered as described hereinbefore for peptide administration in an amount of 0.6 to 1.0 μ g in 2 μ l.

Please amend the Sequence Listing by substituting the Sequence Listing paper copy submitted herewith (5 pages) for the paper copy presently on file (5 pages). A replacement computer readable form is also enclosed herewith. The Sequence Listing has been amended to insert the sequence SEQ ID NO:12. The Sequence Listed is further amended to insert the serial number and filing date of the present application.

Statement pursuant to 37 C.F.R. 1.825(a),(b): The undersigned attorney hereby states that the amendment to the Sequence Listing to add SEQ ID NO:12, which amendment is contained in the replacement paper copy and computer readable form Sequence Listing submitted herewith, is supported by the specification as filed at page 20, lines 23-29. The replacement Sequence Listing in paper copy and computer readable form include no new matter. The content of the

Appl. No. 09/998,491
Reply to March 25, 2004 Office action

replacement computer readable form Sequence Listing is the same as the replacement paper copy submitted herewith.